Lipella Pharmaceuticals Inc (LIPO) FinancialsLIPOLipella Pharmaceuticals Inc

Evaluating the bottom line, Lipella Pharmaceuticals Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1026.22%, while the net margin is -1009.76%. These profitability ratios, combined with a Return on Equity (ROE) of -154.54%, provide a clear picture of how effectively LIPO converts its operational activities into shareholder value.

In the context of the broader market, LIPO competes directly with industry leaders such as CYCC and GNPX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, LIPO's gross margin of 100.00% stands against CYCC's N/A and GNPX's N/A. Such benchmarking helps identify whether Lipella Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.